RESUMEN
Objective To study the effects of calcitonin on bone mineral density(BMD), bone strength and bone fragile fracture in osteoporosis. Methods This is a one year, single centered, prospective and randomized, opening study: 135 patients with osteoporosis were divided into calcitonin+calcium group and calcium group. Patients of calcitonin+calcium group received salmon calcitonin(Miacalcic was injected intramuscularly, 50 IU/day in first week, 50 IU/two days in second week and 50 IU/twice/week later) and calcium(calcium 600 mg/day), patients in another group received calcium(calcium 600 mg/day). The determination markers included serum calcium, serum phosphate, serum alkline phosphatase, osteocalcin and urine hydroxyproline before and after treatment, at same time all patients were examined by DEXA(lumbar, hip) and QUS(radius, tibia). Results After 1 year treatment, 53 patients of calcitonin+calcium group and 59 patients of calcium group were followed up. In calcitonin+calcium group, BMD of lumbar spine increased about 1%(P